| BHC |
Bausch Health Companies Inc. |
72%
|
Reciprocal relationship from BHC graph: Reciprocal relationship from NKTR graph: the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all tim… |
| BHC |
Bausch Health Companies Inc. |
72%
|
the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the study… |
| CTMX |
CytomX Therapeutics, Inc. |
72%
|
Reciprocal relationship from CTMX graph: source for their respective manufacturing and supplies. Failure of any of these contractors could affect our ability to have clinical trial material available… |
| IOBTQ |
IOBTQ |
72%
|
n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| IOBTQ |
IOBTQ |
72%
|
Reciprocal relationship from IOBTQ graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from IOBTQ graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk … |
| LLY |
Eli Lilly and Company |
72%
|
n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Fact… |
| NVO |
Novo Nordisk A/S |
72%
|
Reciprocal relationship from NVO graph: Reciprocal relationship from NKTR graph: . We currently do not intend to sell these securities prior to maturity and it is more likely than not that we will no… |
| NVO |
Novo Nordisk A/S |
72%
|
. We currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis… |
| ODTX |
ODTX |
72%
|
Reciprocal relationship from ODTX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from ODTX graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Fa… |
| ODTX |
ODTX |
72%
|
n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| PLRX |
Pliant Therapeutics, Inc. |
72%
|
Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX g… |
| PSTV |
Plus Therapeutics, Inc. |
72%
|
Reciprocal relationship from PSTV graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PSTV graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PSTV g… |
| SGMO |
Sangamo Therapeutics, Inc. |
72%
|
n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| SGMO |
Sangamo Therapeutics, Inc. |
72%
|
Reciprocal relationship from SGMO graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from SGMO g… |
| SNYNF |
Sanofi |
72%
|
em 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, i… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from NKTR graph: em 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses rela… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the study… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from NKTR graph: the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all t… |
| ASTRAZENECA-AB-BAXALTA-INC |
ASTRAZENECA-AB-BAXALTA-INC |
62%
|
or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the st… |
| AZN |
AstraZeneca PLC |
62%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from NKTR graph: or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all … |
| BIOLOJIC-DESIGN-LTD |
BIOLOJIC-DESIGN-LTD |
62%
|
or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the st… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
he change in the hypothetical amount we and Ampersand would be entitled to receive if Gannet BioChem were liquidated at book value at the end of each period, subject to certain adjustments for any co… |
| F-HOFFMANN-LA-ROCHE-LTD |
F-HOFFMANN-LA-ROCHE-LTD |
62%
|
or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the st… |
| HEALTHCARE-ROYALTY-MANAGEMENT-LLC |
HEALTHCARE-ROYALTY-MANAGEMENT-LLC |
62%
|
or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the st… |
| SANGAMO-THERAPEUTICS-INC-QUELL-THERAPEUTICS-LTD- |
SANGAMO-THERAPEUTICS-INC-QUELL-THERAPEUTICS-LTD- |
62%
|
ubsequently terminated. Following the return of our rights to develop rezpegaldesleukin, we bear all costs of development. We have initiated two Phase 2b rezpegaldesleukin studies: one in patients wi… |
| SONOMA-BIOTHERAPEUTICS-INC-GENTIBIO-INC-KYVEMA-T |
SONOMA-BIOTHERAPEUTICS-INC-GENTIBIO-INC-KYVEMA-T |
62%
|
ubsequently terminated. Following the return of our rights to develop rezpegaldesleukin, we bear all costs of development. We have initiated two Phase 2b rezpegaldesleukin studies: one in patients wi… |
| SYMBIOTIX-LLC |
SYMBIOTIX-LLC |
62%
|
ubsequently terminated. Following the return of our rights to develop rezpegaldesleukin, we bear all costs of development. We have initiated two Phase 2b rezpegaldesleukin studies: one in patients wi… |
| TAKEDA-PHARMACEUTICAL-COMPANY-LTD |
TAKEDA-PHARMACEUTICAL-COMPANY-LTD |
62%
|
or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the st… |
